CIS-TARGETING is the engagement of two receptors on the same cell, a strategy that enables exquisitely selective ligand delivery to the targeted cell types.

TRANS-TARGETING involves engagement of receptors on two different cells, often a tumor cell and an immune cell.

Cis-targeting is the engagement of two molecules on the same cell.  A cis-targeted immunotherapy engages both an immunomodulatory receptor and a specific target that directs the therapy to the desired immune cell type. With this innovative design for immunotherapies, our cis-targeted molecules offer a new level of selectivity, leading to differentiated medicines with optimized efficacy and minimized toxicity.

Our cis-targeting approach is distinct from other targeted immunotherapies that aim to direct the immunomodulator to the location of disease, such as the tumor microenvironment. These local-directed therapeutics generally use a trans-targeting approach, engaging receptors on two different cells, such as tumor cells and immune cells. Trans-targeted immunotherapies often activate many immune cell types in and outside of the intended location, leading to lack of selectivity in their effects.

 

 

 

how we create
cis-targeted immunotherapies

Our cis-targeted immunotherapies are designed to selectively activate specific immune cell types to improve therapeutic outcomes. Our platform can be applied systematically to target multiple classes of immunomodulators and diverse immune cell types, enabling us to develop cis-targeted immunotherapies  spanning multiple therapeutic indications.

At Asher Bio, we have built a discovery platform based on the following steps:

DEFINE
desired biology

In this first step, we select an immunomodulator and interrogate the biology of each immune cell type to determine which cells promote the desired therapeutic benefit and which cells are responsible for side effects and antagonistic effects.

Level of activation of immune cell subtypes in response to immunomodulators

ENGINEER
cis-targeted immunotherapy

We attenuate the affinity of the immunomodulator for its receptor across all cell types. We fuse it with a targeting moiety that binds a specific target only found on the desired immune cell type. This avidity restores activity for only the targeted cell type.

OPTIMIZE
pharmacological profile

We optimize key parameters of our cis-targeted immunotherapy to create the desired pharmacological profile.

 

 
 

This links to an external website.

Continue